250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotech Startup Investors

A list of 50 angel investors and VC funds that invest in Biotech startups. We rank investors based on the number of investments they made in Biotech companies. This investor list updates every month.

Top 50 Biotech Startup Investors

Investor Biotech investments
ARCH Venture Partners 97
OrbiMed 81
Alexandria Venture Investments 75
Sofinnova Partners 70
New Enterprise Associates 69
Versant Ventures 67
Novo Holdings 62
Atlas Venture 61
F-Prime Capital 61
MPM Capital 60
5AM Ventures 60
Polaris Ventures 56
Khosla Ventures 56
Novartis Venture Fund 55
Third Rock Ventures 53
BioAdvance 49
RA Capital Management 47
M Ventures 46
Fifty Years 44
UK Innovation & Science Seed Fund 44
SR One 44
Boehringer Ingelheim Venture Fund 42
Pfizer Venture Investments 42
Canaan Partners 42
Life Sciences Partners 42
Takeda Ventures 41
Bpifrance 40
Frazier Healthcare Partners 40
Lilly Asia Ventures 39
Lux Capital 39
Casdin Capital 39
Connecticut Innovations 38
Seventure Partners 38
DCVC 38
Parkwalk Advisors 38
Hatteras Venture Partners 38
Northpond Ventures 37
Amgen Ventures 37
High-Tech Grunderfonds 36
Life Science Angels 36
The Column Group 36
Boston Harbor Angels 35
Sofinnova Investments 35
Pontifax 34
HealthCap 34
Broadview Ventures 34
Oxford Technology Management 34
Andreessen Horowitz 33
Omega Funds 33
Roche Venture Fund 33
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 23 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, China, Canada
Portfolio highlights
  • Neumora Therapeutics — Pioneering a New Era of Precision Medicines to Restore Brain Health and Wellbeing
  • Rippl Care — Rippl, a mental health organization, is committed to assisting seniors who suffer from dementia and other neurocognitive disorders.
  • Pretzel Therapeutics — Welcome To A New Era In Mitochondrial Therapeutics. Developing treatments to address the genetic roots of mitochondrial dysfunction.
OrbiMed VC Fund · New York, New York, United States · 32 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • Disc Medicine — We are restoring regulation of hepcidin - the link between genetics and erythropoiesis - to create new therapies for patients with inherited and acquired anemias.
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 30 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, France, Canada
Portfolio highlights
  • Matchpoint Therapeutics — Matchpoint aims to discover and develop precision small molecules that harness the power of covalency to bring new possibilities to the treatment of serious immune disease and cancer.
  • Tavros Therapeutics — Tavros Therapeutics is an emerging biotechnology company that discovers and develops therapies for cancer. The company was founded in 2019 and based in Durham, North Carolina.
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 15 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • Abivax — Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients after 11-months of treatment. View the conference presentation, here:
  • F2G — F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity.
  • Inspirna — Innovative Science, breakthrough technology, first-in-class treatments. Learn more
New Enterprise Associates VC Fund · Menlo Park, California, United States · 90 investments in the past 12 months
New Enterprise Associates, Inc. is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’slifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series B, Series A, Series C
  • United States, India, China
Portfolio highlights
  • Partiful — The most memorable parties are planned on Partiful
  • Courtyard — Turn your trading cards, sneakers, watches, and more into tradable Connected Collectibles and earn a percentage of all future sales.
  • Elion — Make better healthcare technology decisions. Elion helps digital health builders discover, evaluate, and select the software and services to power their businesses
Versant Ventures VC Fund · Menlo Park, California, United States · 8 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Vector BioPharma — Vector BioPharma's cutting-edge gene precision delivery technology will transform the safety, efficacy, and specificity of biologics.
  • Tempest Therapeutics — Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
  • Cimeio Therapeutics — Transforming Hematopoietic Stem Cell Transplant and Adoptive Cell Therapies
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 20 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • MedGenome — MedGenome is a developer of sequencing genomics-based diagnostics and research platform intended to improve global health. The company's platform applies genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large population to understand the genetic basis of cancer, metabolic disorders, eyedisorders, and other rare diseases, enabling the healthcare industry to develop deep insights into diseases at the genetic and molecular level.
  • Vestaron — Vestaron produces insecticides for agriculture, animal health, non-crop, and commercial pest control applications. Vestaron Corporation develops and produces insecticides by employing peptides sourced from spiders in the United States. Its products are used in agriculture, animal health, and specialty non-crop applications, as well as in-householdinsects and commercial pest control applications. Vestaron Corporation was formerly known as Venomix, Inc. and changed its name to Vestaron Corporation in August 2009. The company was founded in 2005 and is headquartered in Kalamazoo, Michigan.
  • Disc Medicine — We are restoring regulation of hepcidin - the link between genetics and erythropoiesis - to create new therapies for patients with inherited and acquired anemias.
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 11 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Series C
  • United States, United Kingdom, Germany
Portfolio highlights
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Disc Medicine — We are restoring regulation of hepcidin - the link between genetics and erythropoiesis - to create new therapies for patients with inherited and acquired anemias.
F-Prime Capital VC Fund · Cambridge, Massachusetts, United States · 39 investments in the past 12 months
We create and invest in healthcare and technology companies that improve lives all over the world.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Canary Technologies — Use Canary to securely conduct contactless check-in and process credit card authorizations, contracts, and amenities online. Canary is the only PCI Level-1 Compliant solution for hotel authorizations. Schedule a demo today, and see how we can help your properties reduce chargebacks, save time, and improve the guest experience.
  • ConnexPay — ConnexPay is a payments gateway that connects payment acceptance & issuance for marketplace and intermediary companies. Discover a better way to pay!
  • Neumora Therapeutics — Pioneering a New Era of Precision Medicines to Restore Brain Health and Wellbeing
MPM Capital VC Fund · Cambridge, Massachusetts, United States · 3 investments in the past 12 months
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, Canada, Germany
Portfolio highlights
  • Photys Therapeutics — Photys Therapeutics is a proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function.
  • Aktis Oncology — Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care
  • CODA Biotherapeutics — Coda Biotherapeutics makes tunable gene therapy to treat severe neurological disorders.
5AM Ventures VC Fund · Menlo Park, California, United States · 6 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.
  • Disc Medicine — We are restoring regulation of hepcidin - the link between genetics and erythropoiesis - to create new therapies for patients with inherited and acquired anemias.
  • CAMP4 Therapeutics — CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients.
Polaris Ventures VC Fund · Boston, Massachusetts, United States · 15 investments in the past 12 months
Polaris Partners ​has over 20-year history partnering with ​repeat entrepreneurs and innovators who are improving the way people live and work. The ​multibillion-dollar firm invests in healthcare and technology companies ​across all stages, from founding to profitable growth. ​Polaris has offices in Boston and San Francisco. ​Polaris Partners wasfounded in 1996 and is headquartered in Boston, Massachusetts.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, Singapore, Ireland
Portfolio highlights
  • Folx Health — FOLX offers gender-affirming hormone therapy (HRT) for transgender, nonbinary and intersex people.
  • Neumora Therapeutics — Pioneering a New Era of Precision Medicines to Restore Brain Health and Wellbeing
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Khosla Ventures VC Fund · Menlo Park, California, United States · 72 investments in the past 12 months
Khosla Ventures is a venture capital firm started in 2004 by Vinod Khosla, Co-Founder of Sun Microsystems. The firm provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies.With over $15b assets under management, the firm focuses on a range of areas including consumer, enterprise, education,advertising, financial services, semiconductors, health, big data, agriculture, food, sustainable energy, and robotics. Khosla Ventures is headquartered in Menlo Park, California.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series A, Series B, Seed
  • United States, India, Canada
Portfolio highlights
  • SURGE Therapeutics — SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.
  • Relay — Relay helps to streamline team’s workflows and automate mundane tasks.
  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 7 investments in the past 12 months
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
  • Splice Bio — We are working with our proprietary platform to address key limitations of current gene therapy approaches to treat patients in need.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 4 investments in the past 12 months
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • MOMA Therapeutics — We will discover the next generation of precision medicines by targeting the molecular machines that underlie human disease.
  • Celsius Therapeutics — Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.
  • Septerna — Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs).
BioAdvance VC Fund · Philadelphia, Pennsylvania, United States · 4 investments in the past 12 months
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Seed, Funding Round, Series A
  • United States, Canada
Portfolio highlights
  • Innervace — Innervace is a developer of a regenerative therapy company designed to develop implantable tissue-engineered brain pathways for neurodegenerative disorders.The company is focused on the development and commercialization of anatomically inspired living scaffolds for brain pathway reconstruction, and its lead clinical product is a tissue-engineerednigrostriatal pathway that mimics the lost nigrostriatal pathway in patients with Parkinson's disease. This gives patients access to technology that specifically reconstructs brain pathways rather than just masking symptoms temporarily.Innervace was established in 2018 by in Philadelphia, Pennsylvania
  • Senzo — Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device.
  • Halo Labs — Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States.
RA Capital Management VC Fund · Boston, Massachusetts, United States · 34 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. Their team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. Theyinvest in companies with promising technologies and products. Their approach is to achieve a superior understanding of data, experimental/trial design, regulatory process, and commercial potential. When appropriate, they can offer their portfolio companies leads on in-licensing opportunities and strategic partnerships, as well as insight into the demands of the public markets.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Vaxess Technologies — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
  • Solid Biosciences — Life science company focused on solving Duchenne muscular dystrophy
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
M Ventures VC Fund · Amsterdam, Noord-Holland, The Netherlands · 9 investments in the past 12 months
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Nucleome Therapeutics — Decoding the dark matter of the human genome to deliver first-in-class precision medicinesDiscover More
  • Metalenz — Metalenz develops novel optical elements that exploit structured Huygens' surfaces (metamaterial structures) for controlling wavefronts, polarization, and other properties of light. It provides ultra-thin planar optics for high-resolution full-color imaging and making the lenses used by mobile phones, computers, and other electronic devicessmaller that enable businesses using the optical lenses to get miniaturized, lighter alternatives to established lenses.
  • NeoLogic (VLSI) — NeoLogic was founded to address the increasing workloads of video, artificial intelligence, machine learning, data analytics, and more in the cloud and at the edge. we developer a unique technology that cuts down the transistor count of circuits by a factor of up to 3x at any technology node.
Fifty Years VC Fund · San Francisco, California, United States · 21 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
  • Harmonic Discovery — Harmonic Discovery operates as a pharmaceutical company that develops a platform that combines computing and experimentation.
  • Arpeggio Bio — Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work.
UK Innovation & Science Seed Fund VC Fund · Harwell, Oxfordshire, United Kingdom · 5 investments in the past 12 months
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Seed, Funding Round, Series A
  • United Kingdom, United States
Portfolio highlights
  • Silveray — Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.
  • MIRICO — Detect, localise and quantify emissions with MIRICO's revolutionary technology. Find out how we can help you with your gas monitoring today.
  • Lineat Composites — We introduce a new aligned fibre material format that forms the basis of high-performance sustainable composite materials.
SR One VC Fund · Cambridge, Massachusetts, United States · 8 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Dren Bio — Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 8 investments in the past 12 months
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, Germany, Belgium
Portfolio highlights
  • Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
  • C-mo Medical Solutions — C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.
  • ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
Pfizer Venture Investments VC Fund · New York, New York, United States · 13 investments in the past 12 months
Pfizer Venture Investments is a venture capital firm.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series B, Series A, Series C
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Nucleome Therapeutics — Decoding the dark matter of the human genome to deliver first-in-class precision medicinesDiscover More
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Canaan Partners VC Fund · Menlo Park, California, United States · 36 investments in the past 12 months
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series A, Series B, Series C
  • United States, Israel, United Kingdom
Portfolio highlights
  • Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
  • Alkymi — Alkymi is an intelligent data processing and workflow automation solution designed to empower business users. We help free huge volumes of data from emails and documents to accelerate decision-making.
  • Pin — To help organisations raise VC funding from public sources, Pin handles the annual taxes, supplies the back office, and creates the legal framework. We've designed our funds in a special way to let communities raise money from accredited and unaccredited investors.
Life Sciences Partners VC Fund · Amsterdam, Noord-Holland, The Netherlands · 7 investments in the past 12 months
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example,LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, The Netherlands, Switzerland
Portfolio highlights
  • eTheRNA immunotherapies — eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases.
  • ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
  • Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Takeda Ventures VC Fund · San Diego, California, United States · 6 investments in the past 12 months
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Japan
Portfolio highlights
  • Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
  • Code Biotherapeutics — Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases not well served by other gene therapy technologies.
  • Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Bpifrance VC Fund · Maisons-alfort, Ile-de-France, France · 99 investments in the past 12 months
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Funding Round, Seed, Series A
  • France, United States, Canada
Portfolio highlights
  • Verkor — Verkor is a French industrial company set to amplify battery cell production.
  • Coqli — Coqli manufactures customizable and environmentally friendly corrugated cardboard packaging. Its online solution allows users to easily design and order custom and personalized packaging in complete autonomy. The company was founded in 2019 and is based in Vincey, France.
  • Jeudimerci — JeudiMerci is a marketing platform that enables users to send physical items as easily as an email. It creates a B2B customer experience by seizing every opportunity to create a link with prospects and customers. Its Direct Mail service allows them to trigger the sending of gifts automatically, at key stages of the customer journey.The companywas founded in 2019 and is headquartered in Paris, France.
Frazier Healthcare Partners VC Fund · Seattle, Washington, United States · 3 investments in the past 12 months
Frazier Healthcare Partners: Investing exclusively in healthcare for 25 years.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Post-IPO Equity
  • United States, Canada, Ireland
Portfolio highlights
  • Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
  • Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
  • SanReno Therapeutics — SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China.
Lilly Asia Ventures VC Fund · Shanghai, Shanghai, China · 11 investments in the past 12 months
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
  • China, United States, Hong Kong
Portfolio highlights
  • Neukio Biotherapeutics — Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
  • ClinChoice昆翎 — Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trialdesigns, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China.
  • ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Lux Capital VC Fund · New York, New York, United States · 54 investments in the past 12 months
Lux Capital Management manages of $4 billion in assets focused on founding, seed, early-stage, and growth investments in the physical, material and life sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures our portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Series A, Seed, Series B
  • United States, Canada, Ireland
Portfolio highlights
  • Apex Space — Apex manufactures ESPA-class satellites, ranging from 40 to 400kg. Our first spacecraft bus platform, Aries, is built for LEO missions for earth observation, communications, and more. Configure the Aries bus to meet your specific mission profile.
  • Stairwell — Stairwell helps security teams outsmart any attacker, put intelligence into action, and take back the cybersecurity high ground with the Inception platform.
  • Tines — Tines is an enterprise automation platform designed to help security and ops teams automate manual workloads. With 1,000+ template options for common security actions, Tines is power and simplicity through direct integration with your existing tools. The company was founded in 2018 and is headquartered in Dublin.
Casdin Capital VC Fund · New York, New York, United States · 34 investments in the past 12 months
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series B, Series A, Series C
  • United States, France, China
Portfolio highlights
  • LetsGetChecked — Home lab test kits & healthcare solutions to monitor your health and help diagnose certain conditions, privately and confidentially. Certified, accurate & fast results in 2-5 days. Free shipping both ways!
  • Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
  • Auron Therapeutics — A differentiated approach to cure cancer.
Connecticut Innovations VC Fund · Rocky Hill, Connecticut, United States · 14 investments in the past 12 months
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
  • Health Care, Science/Engineering, Software
  • Series A, Seed, Funding Round
  • United States, Israel, Canada
Portfolio highlights
  • Bags — Grow your business with access to fair and flexible funding options designed to help you do your thing. Bags is the best place for business owners to get dollars for working capital, inventory, marketing, expansion, or anything else you need to grow.
  • Peer Robotics — Peer Robotics is an industrial automation company that provides an easier, flexible, and cost efficient way to integrate and deploy mobile robots. Peer Robotics building out a suite of Collaborative Mobile Robots (CMR) with use-cases in manufacturing, warehousing, and healthcare sectors, the platform is currently live with paid PoCs (Proof ofConcepts).
  • Aceiss — Aceiss provides immediate visibility into user access everywhere, regardless of what technologies you use.
Seventure Partners VC Fund · Paris, Ile-de-France, France · 11 investments in the past 12 months
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Funding Round
  • France, United States, Germany
Portfolio highlights
  • Clinical Microbiomics — Expert microbiome analysis services, including for gut, oral, skin, and for pre clinical & clinical trials.
  • Standing Ovation — Animal-free dairy cheese
  • Sentryc — Protect your brand and your products from counterfeiters with Sentryc. We monitor over 120 marketplaces for you and remove potential counterfeits.
DCVC VC Fund · San Francisco, California, United States · 26 investments in the past 12 months
Deep Tech VC firm with over $3B under management
Show more
Investment focus
  • Software, Science/Engineering, Data and Analytics
  • Seed, Series A, Series B
  • United States, Canada, Australia
Portfolio highlights
  • Smartex.ai — Smartex provides 100% automated real-time inspection for Circular Knitting Machines. Identify defects as they happen, so that you can quickly address the issue & keep your production running.
  • Samsara Eco — Samsara Eco is an enviro-tech company creating infinite recycling to end plastic pollution.
  • Braavos — Braavos is a smart contract based wallet for managing your funds & NFTs and connecting to dApps.
Parkwalk Advisors VC Fund · London, England, United Kingdom · 21 investments in the past 12 months
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Seed, Series A, Series B
  • United Kingdom, United States, Philippines
Portfolio highlights
  • Enhanc3D Genomics — Enhanc3D Genomics is a spinout company from Babraham Institute.
  • Opsydia — Opsydia is set to disrupt a number of industries by its ability to create practically invisible structures inside transparent materials. Permanent and inimitable serial numbers, images or cryptographic data can be laser-written without compromising the integrity of the material or modifying its surface. Material applications include diamond, glassand polymers
  • MoA Technology — We harness the principles of natural selection to accelerate discovery for better, safer herbicides so farmers can continue to feed the world.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States · 6 investments in the past 12 months
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Funding Round
  • United States, Canada
Portfolio highlights
  • Code Biotherapeutics — Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases not well served by other gene therapy technologies.
  • Wildflower Health — Wildflower Health focuses on its client's needs and integrates services into existing sustainability programs. Its team is passionate about harnessing user-centered design and technology to deliver products that drive smarter healthcare decisions. It was founded in 2012 and headquartered in San Francisco, California.
  • Huma.AI — Business Intelligence for Life Sciences. Medical Affairs, Regulatory Affairs, and Clinical Development software. Get insights from Machine Learning.
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 25 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, United Kingdom, Australia
Portfolio highlights
  • EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
  • Vestaron — Vestaron produces insecticides for agriculture, animal health, non-crop, and commercial pest control applications. Vestaron Corporation develops and produces insecticides by employing peptides sourced from spiders in the United States. Its products are used in agriculture, animal health, and specialty non-crop applications, as well as in-householdinsects and commercial pest control applications. Vestaron Corporation was formerly known as Venomix, Inc. and changed its name to Vestaron Corporation in August 2009. The company was founded in 2005 and is headquartered in Kalamazoo, Michigan.
  • Syapse — Syapse is a real-world evidence company dedicated to extinguishing the fear and burden of serious disease by advancing real-world care.
Amgen Ventures VC Fund · San Francisco, California, United States · 11 investments in the past 12 months
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more
Investment focus
  • Biotechnology, Science/Engineering, Health Care
  • Series B, Series A, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
  • BigHat Biosciences — We use machine learning and synthetic biology to design and engineer antibody therapeutics.
  • Kernal Biologics — Kernal biologics is an onco-selective mRNA therapeutics company located in Cambridge, MA
High-Tech Grunderfonds VC Fund · Bonn, Nordrhein-Westfalen, Germany · 47 investments in the past 12 months
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Seed, Series A, Funding Round
  • Germany, Switzerland, United States
Portfolio highlights
  • DeepScenario — DeepScenario provides real-world traffic data with high accuracy to help companies build the world’s most intelligent driver.
  • Grand perspective — Grandperspective scanfeld is the first remote sensing solution for automated early-warning gas leak detection in chemical plants.
  • GS Bavaria — GS Bavaria is a manufacturer of industrial-scale nano-sized carbide powders. The production of the nanomaterials is extremely cost-efficient, sustainable and with minimal energy consumption due to the revolutionary bioleaching extraction process for tungsten, tungsten carbide and other metals.
Life Science Angels VC Fund · Sunnyvale, California, United States
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Funding Round, Seed, Series A
  • United States, Israel, The Netherlands
Portfolio highlights
  • InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
  • Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
The Column Group VC Fund · San Francisco, California, United States · 5 investments in the past 12 months
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Show more
Investment focus
  • Biotechnology, Science/Engineering, Health Care
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Carmot Therapeutics — Drug discovery and development to target the root causes that drive cancer and metabolic diseases using Chemotype Evolution.
  • Remix Therapeutics — Remix Therapeutics is developing small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
  • Plexium — Plexium is the premier, next-generation targeted protein degradation (TPD) company. We lead the way in the rational design and discovery of monovalent protein degraders across a wide range of modalities.Through our comprehensive best-in-class TPD platform, powered by a proprietary high-throughput cell-based screening (uHTS) technology, we arepushing the boundaries of TPD — creating limitless possibilities.
Boston Harbor Angels VC Fund · Boston, Massachusetts, United States
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Angel, Seed, Series A
  • United States, Canada, India
Portfolio highlights
  • Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
  • Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Sofinnova Investments VC Fund · Menlo Park, California, United States · 2 investments in the past 12 months
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series C, Series A
  • United States, France, United Kingdom
Portfolio highlights
  • RayzeBio — Defeating cancer withradiopharmaceuticalmedicines
  • NorthSea Therapeutics — NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
  • Antiva Biosciences — Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.
Pontifax VC Fund · Herzliya, Tel Aviv, Israel · 4 investments in the past 12 months
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, Israel, France
Portfolio highlights
  • Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
  • ARMGO,Pharma,Inc. — ARMGO Pharma, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. It offers rycals, which are calcium release channel stabilizers that act on ryanodine receptor/calcium release channel, a therapeutic target located on thesarcoplasmic/endoplasmic reticulum of the cell for treating chronic heart failure, cardiac arrythmias, and muscle disorders, as well as cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. The company was incorporated in 2004 and is based in Tarrytown, New York with an additional office in New York, New York.
  • Anaveon — Anaveon is a biopharmaceutical company that transforms engineered cytokines into novel life-saving treatments. The first program going into clinical trials is a selective IL-2 receptor agonist.
HealthCap VC Fund · Stockholm, Stockholms Lan, Sweden · 4 investments in the past 12 months
HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with the Odlander Fredrikson Group as their exclusive investments advisor. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized provider of venture capital within life sciences Europe.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series B, Series A, Funding Round
  • United States, Sweden, France
Portfolio highlights
  • Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
  • Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
  • HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
Broadview Ventures VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Seed, Debt Financing
  • United States, Israel, Denmark
Portfolio highlights
  • XII Medical — Minimally Invasive Technology for Obstructive Sleep Apnea.
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
  • CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
Oxford Technology Management VC Fund · Oxford, Oxfordshire, United Kingdom
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Seed, Funding Round, Series A
  • United Kingdom, United States
Portfolio highlights
  • MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
  • OxCan — Enabling curative cancer treatment through early detection
  • Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 181 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Internet, IT
  • Series A, Series B, Seed
  • United States, United Kingdom, Brazil
Portfolio highlights
  • Partiful — The most memorable parties are planned on Partiful
  • UpSmith — UpSmith unlocks high wage, high growth, high purpose, and high dignity careers. Build your future, starting today.
  • Apex Space — Apex manufactures ESPA-class satellites, ranging from 40 to 400kg. Our first spacecraft bus platform, Aries, is built for LEO missions for earth observation, communications, and more. Configure the Aries bus to meet your specific mission profile.
Omega Funds VC Fund · Boston, Massachusetts, United States · 7 investments in the past 12 months
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Photys Therapeutics — Photys Therapeutics is a proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function.
  • eTheRNA immunotherapies — eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases.
  • Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
Roche Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 3 investments in the past 12 months
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series B, Series A, Series C
  • United States, Spain, United Kingdom
Portfolio highlights
  • NMD Pharma — NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
  • Good Therapeutics — Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
  • Freenome — Freenome is a biotechnology company based in South San Francisco that has pioneered the most comprehensive multiomics platform for early cancer detection with a simple blood test.
Investors by industry
Investors by country
Investors in Biotech by country
Angel investors in Biotech by country
VC Funds in Biotech by country